deferoxamine has been researched along with Autoimmune Diabetes in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 7.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 3.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| "Thirteen patients with type 1 diabetes underwent PET using nitrogen-13 ammonia at rest and during sympathetic stimulation with the cold pressor test (CPT)." | 2.70 | Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. ( Bengel, FM; Drzezga, AE; Hattori, N; Nekolla, SG; Rihl, J; Schnell, O; Schwaiger, M; Standl, E, 2002) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| "Risk factors associated with IDDM and IGT were lack of compliance with chelation therapy, iron overload and the presence of cirrhosis and severe fibrosis." | 1.30 | Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. ( De Sanctis, V; Fortini, M; Gamberini, MR; Gilli, G; Testa, MR, 1998) |
| "Insulin-dependent diabetes mellitus (IDDM) is a frequent complication in patients with beta-thalassaemia major." | 1.29 | Diabetes mellitus in children suffering from beta-thalassaemia. ( al-Fawaz, I; al-Swailem, A; el-Hazmi, MA; Warsey, AS, 1994) |
| "Cardiac involvement in hereditary haemochromatosis (HH) is a poor prognostic sign and is the main cause of death in the juvenile form." | 1.29 | Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies. ( Baandrup, U; Bagger, JP; Christensen, T; Ellegaard, J; Jensen, FT; Jensen, PD, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zeinivand, M | 1 |
| Nahavandi, A | 1 |
| Zare, M | 1 |
| Leoncini, S | 1 |
| Rossi, V | 1 |
| Signorini, C | 1 |
| Tanganelli, I | 1 |
| Comporti, M | 1 |
| Ciccoli, L | 1 |
| Hattori, N | 2 |
| Schnell, O | 2 |
| Bengel, FM | 2 |
| Rihl, J | 2 |
| Nekolla, SG | 2 |
| Drzezga, AE | 1 |
| Standl, E | 2 |
| Schwaiger, M | 2 |
| Ooi, GC | 1 |
| Khong, PL | 1 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Cappellini, MD | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 2 |
| Ghilardi, R | 1 |
| Piga, A | 2 |
| Cnaan, A | 1 |
| Reddy, S | 1 |
| Slakter, J | 1 |
| Aaberg, TM | 1 |
| Singh, RP | 1 |
| Kaiser, PK | 1 |
| Roza, AM | 1 |
| Slakey, DP | 1 |
| Pieper, GM | 1 |
| Van Ye, TM | 1 |
| Moore-Hilton, G | 1 |
| Komorowski, RA | 1 |
| Johnson, CP | 1 |
| Hedlund, BE | 1 |
| Adams, MB | 1 |
| el-Hazmi, MA | 1 |
| al-Swailem, A | 2 |
| al-Fawaz, I | 1 |
| Warsey, AS | 1 |
| Jensen, PD | 1 |
| Bagger, JP | 1 |
| Jensen, FT | 1 |
| Baandrup, U | 1 |
| Christensen, T | 1 |
| Ellegaard, J | 1 |
| Fortini, M | 1 |
| Gilli, G | 1 |
| Testa, MR | 1 |
| De Sanctis, V | 2 |
| Zuppinger, K | 1 |
| Molinari, B | 1 |
| Hirt, A | 1 |
| Imbach, P | 1 |
| Gugler, E | 1 |
| Tönz, O | 1 |
| Zurbrügg, RP | 1 |
| Gabutti, V | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Wonke, B | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| Andress, DL | 1 |
| Kopp, JB | 1 |
| Maloney, NA | 1 |
| Coburn, JW | 1 |
| Sherrard, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferoxamine and Autoimmune Diabetes
| Article | Year |
|---|---|
Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in diabetic patients.
Topics: Aged; Case-Control Studies; Deferoxamine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eryt | 2008 |
Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus.
Topics: Ammonia; Cold Temperature; Coronary Circulation; Coronary Vessels; Deferoxamine; Diabetes Mellitus, | 2002 |
13 other studies available for deferoxamine and Autoimmune Diabetes
| Article | Year |
|---|---|
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, | 2020 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Cardiac autonomic dysinnervation and myocardial blood flow in long-term Type 1 diabetic patients.
Topics: 3-Iodobenzylguanidine; Deferoxamine; Diabetes Mellitus, Type 1; Female; Heart; Humans; Iron Chelatin | 2003 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Diagnostic and therapeutic challenges.
Topics: Abdominal Pain; Aged; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Glomerulon | 2007 |
Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female; Hematocrit; | 1994 |
Diabetes mellitus in children suffering from beta-thalassaemia.
Topics: Adolescent; Age Factors; beta-Thalassemia; Blood Glucose; Child; Deferoxamine; Diabetes Mellitus, Ty | 1994 |
Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies.
Topics: Adult; Alanine Transaminase; Biomarkers; Biopsy; Deferoxamine; Diabetes Mellitus, Type 1; Ferritins; | 1993 |
Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Diabetes Mellitus, Type | 1998 |
Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
Topics: Adolescent; Arginine; Blood Glucose; Child; Child, Preschool; Deferoxamine; Diabetes Mellitus, Type | 1979 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |
Early deposition of aluminum in bone in diabetic patients on hemodialysis.
Topics: Aluminum; Bone and Bones; Bone Development; Deferoxamine; Diabetes Mellitus, Type 1; Diabetic Nephro | 1987 |